Phase II SAKK 35/10 Trial of Rituximab with or without Lenalidomide for Patients with Previously Untreated FL


Phase II SAKK 35/10 Trial of Rituximab with or without Lenalidomide for Patients with Previously Untreated FL
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Jonathan W Friedberg, MD, MMSc (1/8/15)
Kimby E et al. Rituximab plus lenalidomide improves the complete remission rate in comparison with rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. Primary endpoint analysis of the randomized phase-2 trial SAKK 35/10. Proc ASH 2014;Abstract 799.

Dr Friedberg is Samuel Durand Professor of Medicine and Director of the Wilmot Cancer Center at the University of Rochester in Rochester, New York.